| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.
|
J Am Soc Nephrol
|
2012
|
2.06
|
|
2
|
Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases.
|
Perit Dial Int
|
2010
|
1.89
|
|
3
|
Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand.
|
Am J Kidney Dis
|
2008
|
1.69
|
|
4
|
Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases.
|
Nephrol Dial Transplant
|
2009
|
1.68
|
|
5
|
The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.
|
Perit Dial Int
|
2012
|
1.63
|
|
6
|
Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with peritoneal dialysis.
|
Perit Dial Int
|
2007
|
1.59
|
|
7
|
Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients.
|
Perit Dial Int
|
2011
|
1.56
|
|
8
|
High membrane transport status on peritoneal dialysis is not associated with reduced survival following transfer to haemodialysis.
|
Nephrol Dial Transplant
|
2007
|
1.51
|
|
9
|
Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients.
|
Kidney Int
|
2009
|
1.49
|
|
10
|
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.
|
Nephrol Dial Transplant
|
2013
|
1.47
|
|
11
|
Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes.
|
Kidney Int
|
2010
|
1.45
|
|
12
|
Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases.
|
Clin J Am Soc Nephrol
|
2009
|
1.31
|
|
13
|
Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases.
|
Am J Kidney Dis
|
2010
|
1.31
|
|
14
|
Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases.
|
Nephrol Dial Transplant
|
2010
|
1.24
|
|
15
|
Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis.
|
Nephrol Dial Transplant
|
2010
|
1.24
|
|
16
|
Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis.
|
Kidney Int
|
2010
|
1.22
|
|
17
|
Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases.
|
BMC Nephrol
|
2009
|
1.16
|
|
18
|
Polymicrobial peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes.
|
Am J Kidney Dis
|
2009
|
1.15
|
|
19
|
Recent peritonitis associates with mortality among patients treated with peritoneal dialysis.
|
J Am Soc Nephrol
|
2012
|
1.10
|
|
20
|
Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases.
|
Nephrol Dial Transplant
|
2009
|
1.09
|
|
21
|
The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.
|
Nephrol Dial Transplant
|
2012
|
1.07
|
|
22
|
Compared with younger peritoneal dialysis patients, elderly patients have similar peritonitis-free survival and lower risk of technique failure, but higher risk of peritonitis-related mortality.
|
Perit Dial Int
|
2011
|
1.05
|
|
23
|
The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study.
|
BMC Nephrol
|
2012
|
1.02
|
|
24
|
Association of dialysis modality and cardiovascular mortality in incident dialysis patients.
|
Clin J Am Soc Nephrol
|
2009
|
1.01
|
|
25
|
Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
|
BMC Nephrol
|
2010
|
0.95
|
|
26
|
Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study.
|
Am J Kidney Dis
|
2011
|
0.94
|
|
27
|
Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease.
|
Kidney Int
|
2012
|
0.93
|
|
28
|
Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations.
|
Nephrol Dial Transplant
|
2005
|
0.91
|
|
29
|
Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function.
|
Nephrol Dial Transplant
|
2011
|
0.90
|
|
30
|
Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study.
|
Nephrol Dial Transplant
|
2011
|
0.88
|
|
31
|
End-stage kidney disease due to scleroderma--outcomes in 127 consecutive ANZDATA registry cases.
|
Nephrol Dial Transplant
|
2011
|
0.87
|
|
32
|
Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomes.
|
Clin J Am Soc Nephrol
|
2013
|
0.85
|
|
33
|
Daily variation in death in patients treated by long-term dialysis: comparison of in-center hemodialysis to peritoneal and home hemodialysis.
|
Am J Kidney Dis
|
2012
|
0.85
|
|
34
|
End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases.
|
Nephrol Dial Transplant
|
2012
|
0.84
|
|
35
|
The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New Zealand.
|
Clin J Am Soc Nephrol
|
2013
|
0.84
|
|
36
|
Effects of climatic region on peritonitis risk, microbiology, treatment, and outcomes: a multicenter registry study.
|
Perit Dial Int
|
2012
|
0.81
|
|
37
|
End-stage kidney disease due to haemolytic uraemic syndrome--outcomes in 241 consecutive ANZDATA registry cases.
|
BMC Nephrol
|
2012
|
0.80
|
|
38
|
Effect of dialysis modality on survival of hepatitis C-infected ESRF patients.
|
Clin J Am Soc Nephrol
|
2011
|
0.78
|
|
39
|
Repeated peritoneal dialysis-associated peritonitis: a multicenter registry study.
|
Am J Kidney Dis
|
2011
|
0.78
|
|
40
|
Trials (and tribulations) of biocompatible peritoneal dialysis fluids.
|
Perit Dial Int
|
2012
|
0.78
|
|
41
|
A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
|
Curr Med Res Opin
|
2008
|
0.76
|
|
42
|
Human peritoneal mesothelial cells isolated from spent dialysate fluid maintain contaminating macrophages via production of macrophage colony stimulating factor.
|
Nephrology (Carlton)
|
2007
|
0.76
|
|
43
|
Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination.
|
Kidney Int
|
2012
|
0.75
|
|
44
|
End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.
|
Am J Nephrol
|
2015
|
0.75
|